Archives
IRP2, TFEB and Macrophage Lysosomal Defense
2026-11-07
A study in mice and macrophage models links myeloid IRP2 deficiency to impaired lysosomal antimicrobial function and liver abscess susceptibility after intestinal injury. Its mechanistic experiments implicate HIF2 activity and lactic-acid metabolism in altered TFEB localization, while human observations provide cross-context concordance rather than evidence of clinical efficacy.
SB-3CT and the Adamtsl3–MMP9 Axis
2026-11-06
Mouse visual-cortex evidence supports a pathway in which Adamtsl3 constrains active MMP9, preserving perineuronal-net integrity around parvalbumin interneurons and limiting adult cortical plasticity. SB-3CT is most informative in this context as a dual gelatinase-pathway probe: its pharmacological rescue logic supports MMP involvement but does not establish an MMP9-exclusive mechanism or therapeutic efficacy.
IRP2, TFEB, and Macrophage Lysosomal Defense
2026-11-06
A study in mice and macrophage models links myeloid IRP2 to lysosomal antimicrobial function during intestinal inflammation. Its findings support a model in which IRP2 influences TFEB localization through HIF2- and lactic-acid-associated signaling, while human observations provide contextual concordance rather than a clinical treatment test.
SB-3CT, MMP9, and Cortical Plasticity
2026-11-05
A source-grounded analysis of how Adamtsl3 constrains MMP9 activity at perineuronal nets, what the mouse visual-cortex study demonstrated, and why pharmacological gelatinase inhibition should not be equated with compound-specific or human therapeutic efficacy.
IRP2, TFEB and Macrophage Antimicrobial Function
2026-11-05
A paper-centred interpretation of how IRP2 links macrophage lysosomal competence to bacterial clearance during intestinal inflammation, with emphasis on TFEB localization, HIF2 activity, lactic-acid metabolism, and the limits of translating mouse and biopsy observations into human disease claims.
IRP2, TFEB and Macrophage Antimicrobial Defense
2026-11-04
A literature-focused analysis of how IRP2 connects iron homeostasis to TFEB-dependent lysosomal function, macrophage bacterial clearance, and protection from inflammation-associated liver abscesses, while separating genotype-identification tools from the study’s mechanistic evidence.
IRP2, TFEB, and Macrophage Lysosomal Defense
2026-11-04
The paper examines how myeloid IRP2 supports macrophage lysosomal antimicrobial activity during intestinal inflammation. Its findings connect impaired post-uptake bacterial clearance with altered TFEB localization and implicate HIF2-linked lactic-acid metabolism, while human observations provide disease-context concordance rather than evidence of treatment efficacy.
IRP2 and Macrophage Lysosomal Defense
2026-11-03
An integrated mouse and macrophage study links IRP2 loss to defective post-phagocytic bacterial clearance through impaired lysosomal acidification and TFEB regulation. HIF2 and lactic-acid perturbations reversed TFEB mislocalization in the reported models, while Crohn’s disease and biopsy data provided cross-context concordance rather than a treatment test.
HNRNPU Lactylation and Cervical Cancer Metabolism
2026-11-03
A literature-focused analysis of how HNRNPU K181 lactylation may connect lactate accumulation to PHGDH-dependent serine metabolism and cervical cancer growth, while separating genetic evidence from the broader pharmacology of pazopanib and the distinct role of (R)-MG132 as a proteasome-control compound.
IRP2, Lysosomes, and Macrophage Defense
2026-11-02
A mechanistic editorial on how IRP2 links iron homeostasis to TFEB-dependent lysosomal function, bacterial clearance, and liver-abscess susceptibility, while distinguishing genotype-confirmation sample preparation from immune-function evidence.
Adamtsl3, MMP9, and Perineuronal-Net Plasticity
2026-11-02
A preclinical study links Adamtsl3 loss in parvalbumin interneurons to altered perineuronal nets, increased MMP9 activity, impaired inhibition, and renewed visual-cortical plasticity. The findings support an Adamtsl3–MMP9 pathway in mouse visual cortex while remaining bounded to the tested genetic, cellular, and pharmacological models.
Adamtsl3, MMP9, and Cortical Plasticity
2026-11-01
A preclinical mouse study examines how Adamtsl3 shapes perineuronal nets around parvalbumin-positive interneurons and tests whether MMP9 activity connects Adamtsl3 loss to altered inhibition and adult visual-cortical plasticity.
When Context Changes What a Result Means
2026-10-31
The same molecular or cellular result can support different conclusions depending on the model, comparator, perturbation and readout. The cervical-cancer study of HNRNPU K181 lactylation illustrates how genetic, biochemical, metabolic and pharmacological contexts strengthen a mechanistic narrative while also limiting what can be attributed to a control compound such as (R)-MG132.
IRP2, TFEB and Macrophage Lysosomal Defense
2026-10-30
A paper-centred interpretation of how myeloid IRP2 supports macrophage lysosomal antimicrobial function during intestinal inflammation, with emphasis on TFEB localization, HIF2 activity and lactic-acid metabolism.
IRP2, TFEB, and Macrophage Lysosomal Defense
2026-10-30
A mouse and macrophage study links myeloid IRP2 to lysosomal antimicrobial capacity during intestinal inflammation. The findings place impaired TFEB localization downstream of altered HIF2 and lactic-acid signaling, while human inflammatory-bowel-disease observations provide cross-context support rather than evidence of clinical treatment efficacy.